About Us

Reactivating Pathways to Healing

Caeregen Therapeutics is focused on discovering and developing novel drug therapies which repair, restore, and protect damaged and diseased tissues by reactivating the pathways and signaling which accompanies normal cellular and tissue development

Caeregen Therapeutics Leadership Team

dr-michael-trese-min

Incoming (2019) president, Club Jules Goninand past president, Retina Society−Developed Jetrea® from concept to clinic and sale to Thrombogenics ($250M)

Michael T. Trese, MD

Co-Founder and Chief Technology Officer
dr-kimberly-drenser

PhD in Molecular Genetics and Microbiology (UF)− Director of Pediatric Retinal Disease Molecular Genetics Laboratory at Oakland University Eye Research Institute.

Kimberly A. Drenser, MD PhD

Co-Founder and Chief Science Officer
dr-antonio-capone-min

Associated Retinal Consultants, Royal Oak, MI−President, Pediatric Retinal Research Foundation−Extensive clinical trial experience.

Antonio Capone, Jr, MD

Co-Founder and Chief Medical Officer
Mr.Capone

Deep drug development back-ground, having ushered >25 drugs from various phases of development to commercial/clinical use−Former CEO/President, Multiple Myeloma Research Foundation.

Walter M. Capone, MBA

Chief Executive Officer and President
Wendy Dailey

Over 30 years conducting eye research. Spanning basic, translational and product development.

Wendy Dailey, B.S.

Research Manager

Scientific Advisory Board

Ambati4

Expert in age-related macular degeneration Vice Chair for Research and founder of the Center for Advanced Vision Science, University of Virginia

Jayakrishna Ambati, MD

Aiello2

Expert in diabetic retinopathy Director of Beetham Eye Institute at Joslin Diabetes Center, Harvard Medical School

Lloyd-Paul Aiello, MD PhD

Blumenkranz2

Extensive innovations in intravitreal, gene and surgical adjuvant drug therapy. Founding Director of the Byers Eye Institute at Stanford

Mark S. Blumenkranz, MD MMS

Ferrara4

Discovered vascular endothelial growth factor (VEGF), Senior Deputy Director, Basic Science at UC San Diego

Napoleone Ferrara, MD

Ferrara2

MD PhD Specialist in vitreoretinal diseases and surgery, including pediatric vitreoretinopathies Clinical professor at University of California at San Diego

Eric Nudleman, MD, PhD

Smith2

Expert in retinopathy of prematurity and vascular growth mechanisms. Professor of Ophthalmology, Harvard Medical School

Lois H. Smith, MD PhD

OUR PARTNERS

Research Partners & Institutions

Industry Partners

Investors & Funding

FOR INVESTORS

Learn more about investing in our innovation.

News & Insights